clinical trial · NCT07105111
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
SchizophreniaSchizoaffective DisorderBipolar DisorderMajor Depressive DisorderTardive DyskinesiaValbenazine
brief summary
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
started
Aug 29, 2025
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Jun 11, 2026
official title
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol